WilmerHale Advises Georgiamune on $75M Series A Financing

WilmerHale Advises Georgiamune on $75M Series A Financing

Client News

Related Solutions

Helping clients launch their businesses and transform their innovative ideas into successful companies.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.

On August 9, 2023, Georgiamune Inc., a privately held, clinical stage biotechnology company, announced the clearance of its Investigational New Drug application by the US Food and Drug Administration for GIM-122, a dual-functioning monoclonal antibody. Furthermore, the company successfully completed a $75M Series A financing, positioning Georgiamune as a promising new biotechnology company in the fields of oncology and autoimmune diseases. General Catalyst and Parker Institute for Cancer Immunotherapy (PICI) co-led the round, while Mubadala Capital, Alexandria Venture Investments, Catalio Capital Management, CJNV BioVenture, and Verition Fund Management provided additional funding.

The WilmerHale team representing Georgiamune was led by Rosemary Reilly, Frances Mosley, Alex Bloom and Jane Cha. 

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.

I Accept Cancel